Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2024 07:00 ET | Source: Tourmaline Bio, Inc.

Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)

Tourmaline plans to accelerate the initiation of a pivotal Phase 3 trial in 2024 evaluating subcutaneous TOUR006 every 8 weeks as first-line treatment for TED, with topline data expected in 2026 ...
December 15, 2023 16:00 ET | Source: Tourmaline Bio, Inc.

Tourmaline Bio added to the NASDAQ Biotechnology Index

NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically...
December 14, 2023 07:30 ET | Source: Tourmaline Bio, Inc.

Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board

NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically...
November 01, 2023 08:00 ET | Source: Tourmaline Bio, Inc.

Tourmaline Bio to Present at Upcoming Investor Conferences

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of...
October 19, 2023 17:37 ET | Source: Tourmaline Bio, Inc.

Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million

Tourmaline will be focused on advancing TOUR006, its differentiated anti-IL-6 antibody, to treat thyroid eye disease (TED), atherosclerotic cardiovascular disease (ASCVD) and other diseases ...
October 17, 2023 17:47 ET | Source: Talaris Therapeutics, Inc.

Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio

Combined Company to Trade on Nasdaq Under Ticker “TRML”Talaris Announces 1-for-10 Reverse Stock Split of Common Stock BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq:...
October 06, 2023 17:09 ET | Source: Talaris Therapeutics, Inc.

Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio

Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE)...
September 20, 2023 08:00 ET | Source: Tourmaline Bio, Inc.

Tourmaline Bio Appoints Gerhard Hagn as SVP, Head of Commercial and Business Development

NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of...
August 28, 2023 07:30 ET | Source: Tourmaline Bio, Inc.

Tourmaline Bio Announces FDA Clearance of Investigational New Drug (IND) Application for TOUR006, an anti-IL-6 antibody with a differentiated profile for the treatment of thyroid eye disease (TED)

NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of...
June 22, 2023 07:30 ET | Source: Talaris Therapeutics, Inc.

Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement

Merger to create Nasdaq-listed, late-stage clinical biotechnology company focused on developing Tourmaline’s anti-IL-6 antibody (TOUR006) in thyroid eye disease (TED) and atherosclerotic...